The difference in medical costs between carbapenem-resistant Acinetobacter baumannii and non-resistant groups: a case study from a hospital in Zhejiang province, China
Crossref DOI link: https://doi.org/10.1007/s10096-017-3088-3
Published Online: 2017-08-23
Published Print: 2017-10
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Zhen, X.
Chen, Y.
Hu, X.
Dong, P.
Gu, S.
Sheng, Y. Y.
Dong, H. http://orcid.org/0000-0002-5064-7297
Funding for this research was provided by:
Pfizer Investment Co. Ltd.
License valid from 2017-08-23